Showing results (1251-1260 of 1,302) with videos related to

Sort By:
Pageof 131
Annals of Neurology|September 24, 2022
Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint InhibitorsXavier Boumaza, Baptiste Bonneau, Damien Roos-Weil, et al.
Brain : a Journal of Neurology|September 30, 2019
Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesisSebastian Herich, Tilman Schneider-Hohendorf, Astrid Rohlmann, et al.
Journal of Autoimmunity|March 5, 2025
Differences in innate immune cell populations distinguish autoimmune from herpesvirus-associated encephalitisSaskia Räuber, Andreas Schulte-Mecklenbeck, Kelvin Sarink, et al.
Cell Reports. Medicine|June 25, 2024
Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathyMarie Deffner, Tilman Schneider-Hohendorf, Andreas Schulte-Mecklenbeck, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
Journal of Neuro-Oncology|September 20, 2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 25, 2011
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extensionSocrates Papapoulos, Roland Chapurlat, Cesar Libanati, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 19, 2011
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fracturesMatthew Austin, Yu-Ching Yang, Eric Vittinghoff, et al.
Journal of Medicinal Chemistry|October 13, 2011
Highly potent, selective, and orally active phosphodiesterase 10A inhibitorsMichael S Malamas, Yike Ni, James Erdei, et al.
Pageof 131